PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
36.51
+0.21 (+0.58%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close36.30
Open36.49
Bid0.00 x 800
Ask0.00 x 1100
Day's Range36.40 - 36.63
52 Week Range32.32 - 39.43
Volume26,613,610
Avg. Volume21,197,695
Market Cap213.568B
Beta0.93
PE Ratio (TTM)10.14
EPS (TTM)3.60
Earnings DateJul 31, 2018
Forward Dividend & Yield1.36 (3.74%)
Ex-Dividend Date2018-05-10
1y Target Est39.86
Trade prices are not sourced from all markets
  • Investing Insights: Conference Highlights and Mind the Gap
    Morningstar9 days ago

    Investing Insights: Conference Highlights and Mind the Gap

    Discussions with Mellody Hobson and Jeremy Grantham; Pfizer; and oil prices on this week's edition.

  • Zacks Value Trader Highlights: General Electric, Starbucks, Pfizer and ExxonMobil
    Zacks3 days ago

    Zacks Value Trader Highlights: General Electric, Starbucks, Pfizer and ExxonMobil

    Zacks Value Trader Highlights: General Electric, Starbucks, Pfizer and ExxonMobil

  • DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus
    Zacks3 days ago

    DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus

    Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.

  • 3 Big Stock Charts for Thursday: JPMorgan Chase, Pfizer and Disney
    InvestorPlace4 days ago

    3 Big Stock Charts for Thursday: JPMorgan Chase, Pfizer and Disney

    After moving dangerously close to the tipping point on Tuesday, the market got something of a reprieve with Wednesday’s action. FANG stocks Facebook (NASDAQ:FB) and Netflix (NASDAQ:NFLX) both moved to record highs yesterday, pulling the rest of the market up with them.

  • Investors Are Undervaluing Pfizer Inc (NYSE:PFE) By 43.43%
    Simply Wall St.4 days ago

    Investors Are Undervaluing Pfizer Inc (NYSE:PFE) By 43.43%

    In this article I am going to calculate the intrinsic value of Pfizer Inc (NYSE:PFE) by taking the expected future cash flows and discounting them to their present value. ThisRead More...

  • Financial Times4 days ago

    [$$] Beijing woos foreign businesses as US trade war looms

    Xi Jinping has enlisted foreign CEOs to help China in its trade showdown with the US. About 20 multinational executives, including representatives from several American companies, met the Chinese president and top officials for more than an hour on Thursday. A six-minute report that opened Chinese state television’s evening news broadcast showed the businessmen listening intently, taking notes and applauding as Mr Xi decried protectionism and extolled the benefits of China’s One Belt, One Road programme and investment environment.

  • How Long Should You Own a Stock?
    Zacks4 days ago

    How Long Should You Own a Stock?

    These 4 criteria can guide investors through the investing maze.

  • Should You Buy Pfizer Inc (NYSE:PFE) At This PE Ratio?
    Simply Wall St.4 days ago

    Should You Buy Pfizer Inc (NYSE:PFE) At This PE Ratio?

    Pfizer Inc (NYSE:PFE) is trading with a trailing P/E of 9.9x, which is lower than the industry average of 24x. Although some investors may jump to the conclusion that thisRead More...

  • Amgen Gets EU Nod to Add Survival Data on Blincyto's Label
    Zacks5 days ago

    Amgen Gets EU Nod to Add Survival Data on Blincyto's Label

    Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.

  • A Look at Allergan’s Valuation as of June 19
    Market Realist5 days ago

    A Look at Allergan’s Valuation as of June 19

    Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.

  • Sarepta's Stock Soars on Encouraging Gene Therapy Results
    Zacks5 days ago

    Sarepta's Stock Soars on Encouraging Gene Therapy Results

    Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.

  • Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks
    Motley Fool5 days ago

    Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks

    J&J's dividend is good. But these are even better.

  • Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx
    Zacks6 days ago

    Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

    The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.

  • Business Wire6 days ago

    Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts

    Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 31, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.

  • Myriad Stock Rose on FDA Supplementary Premarket Approval
    Market Realist6 days ago

    Myriad Stock Rose on FDA Supplementary Premarket Approval

    On June 18, Myriad Genetics (MYGN) announced that the FDA accepted its supplementary premarket approval (or sPMA) application for BRACAnalysis CDx, a companion diagnostic with Pfizer’s (PFE) talazoparib, a PARP (poly ADP ribose polymerase) inhibitor. Pfizer has already filed a new drug application (or NDA) for the approval of talazoparib. The FDA has granted Pfizer’s NDA for talazoparib “priority review” status and provided a Prescription Drug User Fee Act action date of December 2018.

  • Financial Times6 days ago

    [$$] Britain’s flawed medicines regime urgently needs reform

    The UK pharmaceuticals industry and the patients who rely on it are under serious threat from Brexit as well as from the flawed way medicines are developed, tested and made available to patients in the country. Leaders of our industry, which employs more than 140,000 people in the UK and contributes £30bn to gross domestic product, are meeting members of the government, including business secretary Greg Clark and international trade secretary Liam Fox, on Tuesday to discuss the country’s future as a world-leading life sciences hub. A report I compiled with PwC found that it remains a significant barrier to UK investment for many global companies.

  • Reuters7 days ago

    FOCUS-How U.S. tax reform rewards companies that shift profit to tax havens

    The corporate tax cut passed by U.S. President Donald Trump and fellow Republicans that was in part designed to help dissuade U.S. companies from moving profits overseas may instead make the practice a lot more rewarding. The new tax bill cuts the overall corporate tax rate to 21 percent, and allows income from overseas to be taxed at about half that rate – to as low as 10 percent. AbbVie Inc. is a case in point.

  • Investopedia7 days ago

    5 Drug Stocks With Fat Payouts

    Big Pharma is struggling to keep up with the rest of the market this year as tepid revenue, growth, the expiration of key patents, and the likelihood of the government imposing tighter cost controls hold back its performance prospects. Earlier this month, while the broader S&P 500 was yielding just 2%, the dividend yield on the big drug companies in the index was nearly a full percentage point higher at 2.9%.

  • Better Buy: Pfizer Inc. vs. Johnson & Johnson
    Motley Fool8 days ago

    Better Buy: Pfizer Inc. vs. Johnson & Johnson

    How do these two big pharma stocks compare in a head-to-head match?

  • 25 Blue-Chip Stocks That Mutual Fund Managers Love Most
    Kiplinger9 days ago

    25 Blue-Chip Stocks That Mutual Fund Managers Love Most

    Investors continue to pour money into passive vehicles such as indexed mutual funds and exchange-traded funds. However, good old-fashioned stock picking and asset allocation with a human touch still rules in some areas - including in the well-trodden world of blue-chip stocks. After all, actively managed mutual funds run by professional portfolio managers still dwarf their passive cousins. At the end of 2017, actively managed funds had a total of $11.4 trillion in assets under management, according to Morningstar. Passive funds and ETFs controlled $6.7 trillion in assets. As we've noted before, the "smart money" doesn't always live up to the high fees and hype, but it's worth keeping tabs on what they're doing nonetheless. That's even more true for actively managed mutual funds. After all, they comprise a much larger swath of institutional investor dollars. Using data from Morningstar Direct, we were able to discover which blue-chip stocks are most widely held by the biggest actively managed U.S. mutual funds. In other words, these are the 25 most popular stock picks among professional portfolio managers. Not every one of the following stocks is necessarily a buy at current levels, but it's fair to say that they are all superstar companies. And the most popular pick of all probably will surprise you. SEE ALSO: 53 Best Dividend Stocks for 2018 and Beyond

  • Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
    Motley Fool9 days ago

    Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers

    These two small biotechs with promising NASH drugs could attract several big suitors.

  • InvestorPlace10 days ago

    Can Sprout Pharma’s Latest Revival Really Boost VRX Stock?

    Now, Sprout Pharmaceuticals will make a second attempt to sell the drug but using a different method. Most importantly, Sprout will sell the drug for just $400, a 50% markdown from Valeant’s selling price. Both companies have an interest in getting patients prescribed on Addyi.

  • MarketWatch11 days ago

    ViiV Healthcare reports positive results for late-stage HIV trials

    ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, reported on Thursday positive early results from two late-stage trials testing its two-drug regimen in patients new to HIV treatment relative to a three-drug regimen. GlaxoSmithKline shares rose 2.4% in premarket trade on Thursday after the news. It plans to file for regulatory approvals of the two-drug regimen, composed of the drugs dolutegravir and lamivudine, later this year, and also has plans to present full results at an upcoming scientific meeting.